# KPV legal status: the KPV peptide FDA 503A category and compounding access > KPV legal status: not an FDA-approved drug, a research-only peptide, and individually named on the FDA PCAC agenda for July 23-24, 2026 as a bulk substance under evaluation. General information, cited to FDA. Where access actually stands today — research-only, under active FDA review, and named on a scheduled compounding-advisory agenda. General information, not medical or legal advice. ## The short version Here is the KPV legal status in plain terms: KPV is not an FDA-approved drug, and today it is sold only as a research chemical for laboratory use. But the door is not closed — access is under active FDA review and may widen in 2026. KPV is individually named on the published agenda of an FDA advisory committee meeting set for July 23-24, 2026, where it will be discussed as a candidate for a list of substances that compounding pharmacies can use [18]. That is a scheduled discussion, not a decision, and it does not change anything about KPV's status right now. Below is how legal compounded-peptide access works in general — no pharmacies, clinics, or vendors named. ## The Current Fact: Research-Only, Not FDA-Approved KPV — the C-terminal tripeptide (lysine-proline-valine) of alpha-melanocyte-stimulating hormone (alpha-MSH) — is a research peptide and is not an FDA-approved drug for any indication [16][18]. FDA approval of a finished drug is a separate question from whether a substance may be used in pharmacy compounding, and KPV has neither [16]. Under the U.S. Federal Food, Drug, and Cosmetic Act, a bulk drug substance (an active ingredient used as a starting material, rather than a finished approved drug) may be used in 503A pharmacy compounding only if it has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list [16]. Substances not yet on that list are evaluated by FDA through a public nomination process, informed by the Pharmacy Compounding Advisory Committee (PCAC) [16]. KPV is one of the bulk drug substances FDA has scheduled for PCAC evaluation — and being under evaluation is not the same as being on the bulks list or approved for compounding [18]. KPV's present-tense status is best stated exactly that way: a research peptide, not FDA-approved, scheduled for PCAC evaluation. ## Under Active Review: The July 2026 PCAC Agenda The forward-leaning part of the story is real, and it is anchored to one verifiable fact. KPV is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23-24, 2026, listed as a bulk drug substance "being considered for inclusion on the 503A Bulks List" [18]. FDA's calendar evaluates KPV in both its free base and acetate forms, and the same agenda also lists BPC-157, TB-500, and MOTs-C [18]. That is a scheduled evaluation and discussion only. A PCAC discussion is advisory; it is not a listing decision, not a reclassification, and not a change in KPV's current status [16][18]. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by PCAC — so being on the agenda means the question is being examined, nothing more [16]. The outcome of the July 2026 meeting is unknown and should not be assumed or dated [18]. What can be said honestly is the momentum: access is under active FDA review and may expand in 2026. What cannot be said is that any change has already happened — reports of a broader 2026 reclassification or of specific substances being "removed" earlier in 2026 remain unconfirmed against authoritative FDA sources and are not treated as fact here [17]. Note on category: the audited FDA reference does not assign KPV a numbered 503A "Category." KPV is not among the substances with a confirmed category placement, so none is stated here; its status is simply research peptide, not FDA-approved, scheduled for PCAC evaluation [18]. ## How Legally Compounded Peptide Access Works Compounding operates within a defined framework. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally pursuant to a valid prescription for an individual patient; Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight [16]. In general terms, a legally compounded medication is prepared only after an individual patient is evaluated by an appropriately licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription [19]. The pathway runs in order: a licensed-prescriber evaluation — for which telehealth can serve as a front-end consultation channel — then a valid, patient-specific prescription, then dispensing by a state-licensed 503A compounding pharmacy or, for office/batch use, sourcing from an FDA-registered 503B outsourcing facility [19]. Telehealth is a route to that prescriber evaluation, not a separate legal status; it does not expand which substances may be compounded or remove the need for a legitimate clinical relationship and a valid prescription [19]. And there is a hard ingredient-eligibility caveat: a compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules, and an ingredient FDA has flagged for significant safety risks is not eligible for routine 503A compounding while that status stands [19]. For KPV specifically, the eligibility question is exactly what the July 2026 PCAC evaluation is set to examine [18]. ## KPV Side Effects and Safety on the Record ### What are KPV peptide side effects? No human side-effect profile of KPV has been published, because there are no human trials; safety is characterized only in preclinical models, and KPV remains a research-only chemical [16][20]. The KPV peptide side effects question therefore has no clinical answer — what exists is cell and animal data, not a human safety record. This is general information about the regulatory landscape, not medical or legal advice, and not an offer to sell or supply any substance. ### Is KPV legal? KPV is not an FDA-approved drug and is sold as a research chemical for laboratory use only; it is not approved as a drug or dietary supplement in any major jurisdiction [16][20]. Under the FD&C Act it could be used in 503A compounding only if it were on FDA's 503A bulks list or otherwise eligible — and KPV is currently a candidate under PCAC evaluation, not a listed substance [16][18]. ### What is the FDA 503A status of KPV? KPV is a bulk drug substance "being considered for inclusion on the 503A Bulks List," individually named on the FDA PCAC agenda for the meeting scheduled July 23-24, 2026, in both free base and acetate forms [18]. The audited FDA reference does not assign KPV a numbered 503A Category; its present-tense status is research peptide, not FDA-approved, scheduled for PCAC evaluation — a step in evaluation, not a final listing decision [16][18]. ### Can you get KPV from a compounding pharmacy? Legally compounded access requires an eligible ingredient plus a licensed-prescriber evaluation and a valid, patient-specific prescription routed through a 503A pharmacy or 503B outsourcing facility [19]. Because KPV is currently a candidate under FDA evaluation rather than a listed bulk substance, its eligibility for routine 503A compounding is exactly the open question the July 2026 PCAC meeting is scheduled to examine; no future outcome should be assumed [16][18]. --- A blacklight-poster field guide to the KPV tripeptide — every colitis, mechanism, and corneal figure read straight off the published record and cited to source, the no-human-data and research-only lines glowing in plain sight; no clinic behind the poster and nothing here dispensed or sold.